Abstract：
Objectives: This review aims to present recent innovations and advancements in attention-deficit/hyperactivity disorder (ADHD) care, encompassing international consensus statement, new medication formulations, digital therapeutics, and neurostimulation devices. Methods: A comprehensive literature search of relevant articles published in the past five years was conducted, emphasizing the evidence base, efficacy, safety, and practical implications of these advancements. Results: The World Federation of ADHD Consensus Statement offers an updated diagnostic and treatment framework rooted in global scientific evidence. There are several newer ADHD medication formulations, including a nonstimulant (Viloxazine extended release) and the first transdermal amphetamine patch approved to treat ADHD. These options offer some unique benefits to personalize treatment based on symptom profile, lifestyle, preferences, and response. Digital tools offer additional means to restructure environments for individuals with ADHD, reducing impairment and reliance on others. In addition, digital therapeutics enhance access, affordability, personalization, and feasibility of ADHD care, complementing or augmenting existing interventions. Trigeminal nerve stimulation emerges as a well-tolerated nonpharmacological, device-based treatment for pediatric ADHD, with initial trials indicating effect sizes comparable to nonstimulant medications. Conclusions: These innovations in ADHD care represent clinically significant new treatment options and opportunities for personalized care. Health care professionals should integrate these developments into clinical practice, mindful of individual patient and family needs and preferences. Future research should assess long-term outcomes, cost-effectiveness, and acceptability of these innovations.
摘要：
目标：这篇综述旨在介绍注意力缺陷/多动障碍（ADHD）护理的最新创新和进步。包括国际共识声明，新的药物配方，数字疗法，和神经刺激装置。方法:对近5年发表的相关文章进行全面文献检索,强调证据基础，功效,安全,以及这些进步的实际意义。结果：世界多动症联盟共识声明提供了根植于全球科学证据的最新诊断和治疗框架。有几种较新的多动症药物配方，包括非兴奋剂（维洛嗪缓释）和第一个批准用于治疗ADHD的经皮苯丙胺贴剂。这些选项提供了一些独特的好处，可以根据症状概况个性化治疗，生活方式,preferences,和回应。数字工具为患有多动症的个人提供了重建环境的额外手段，减少损害和对他人的依赖。此外,数字疗法增强了访问，负担能力，个性化,多动症护理的可行性，补充或加强现有的干预措施。三叉神经刺激是一种耐受性良好的非药物治疗，基于设备的小儿多动症治疗，初步试验表明，效果大小与非兴奋剂药物相当。结论：ADHD护理的这些创新代表了临床上重要的新治疗选择和个性化护理的机会。卫生保健专业人员应将这些发展融入临床实践，注意个体患者和家庭的需求和偏好。未来的研究应该评估长期结果，成本效益，以及这些创新的可接受性。
